Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment

被引:34
|
作者
Cacciapaglia, Fabio [1 ]
Anelli, Maria Grazia [1 ]
Rinaldi, Angela [1 ]
Fornaro, Marco [1 ]
Lopalco, Giuseppe [1 ]
Scioscia, Crescenzio [1 ]
Lapadula, Giovanni [1 ]
Iannone, Florenzo [1 ]
机构
[1] Univ Bari Aldo Moro, Rheumatol Unit, Dept Emergence Med & Transplantat DETO, I-70124 Bari, Italy
关键词
CARDIOVASCULAR EVENTS; DENSITY-LIPOPROTEIN; AMERICAN-COLLEGE; RISK; DISEASE; LDL; INFLAMMATION; BLOCKADE; THERAPY; ADALIMUMAB;
D O I
10.1155/2018/2453265
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rheumatoid arthritis (RA) patients are at high risk of cardiovascular (CV) events, and the chronic inflammatory state may generate quantitative and qualitative changes in lipoprotein fractions. The anti-IL-6 receptor tocilizumab (TCZ), even if effective in inflammation and joint damage prevention, determined significant alterations to RA patients' lipid levels in randomized controlled trials, but real-world data are lacking. We evaluated the changes in lipid fraction levels and disease activity in a longitudinal cohort of RA patients on long-term treatment with tocilizumab (TCZ) in a community setting. We retrospectively selected 40 naive-biologic RA patients on treatment with intravenous TCZ compared to 20 RA patients on methotrexate treatment as the control group. Total cholesterol (Tot-Chol), low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels were measured at the baseline and at 12, 24, and 52 weeks thereafter. At the same points, 28-joint disease activity score (DAS28), clinical disease activity index (CDAI), and EULAR clinical responses were also assessed. During the first 24 weeks, we observed in TCZ-treated patients a progressive statistically significant (p < 0.001) increase in Tot-Chol, LDL, HDL, and TG, which returned close to the baseline at 52 weeks. But no changes in the lipid-related CV risk indices Tot-Chol/HDL and LDL/HDL ratios and the atherogenic index (log(10) TG/HDL) were detectable. Notably, we observed a statistically significant negative correlation between changes in lipid fractions and DAS28 or CDAI. The prolonged treatment with TCZ was associated to a transient increase in cholesterol's fractions during the first 6 months of treatment, with inverse correlation to disease activity, but with no impact on surrogate lipid indices of atherogenic risk. These findings may aid clinicians in interpreting the RA patient's lipid profile in daily clinical practice.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
    van Vollenhoven, Ronald F.
    Rubbert-Roth, Andrea
    Sebba, Anthony
    Porter-Brown, Benjamin
    Rowell, Lucy
    Napalkov, Pavel
    Smart, Devi
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S1005 - S1005
  • [32] Safety of Tocilizumab in Patients with Rheumatoid Arthritis: An Interim Analysis of Long-Term Extension Trials with a Mean Treatment Duration of 1.5 Years
    Haraoui, Boulos
    van Vollenhoven, Ronald F.
    Smolen, Josef S.
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2596 - 2596
  • [33] Safety of tocilizumab in patients with rheumatoid arthritis: An interim analysis of long-term extension trials with a mean treatment duration of 1.5 years
    van Vollenhoven, Ronald F.
    Smolen, Josef
    Tony, Hans P. T.
    Codding, Christine
    Keystone, Ed C.
    Woodworth, Thasia
    Alecock, Emma
    Alten, Ricke
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S784 - S785
  • [34] CHANGES IN LIPOPROTEINS ASSOCIATED WITH TOCILIZUMAB TREATMENT DO NOT INFLUENCE THE ATHEROGENIC INDEX OF PLASMA OF RHEUMATOID ARTHRITIS PATIENTS
    Cacciapaglia, F.
    Grazia, A. Maria
    Rinaldi, A.
    Scioscia, C.
    Lopalco, G.
    Covelli, M.
    Iannone, F.
    Lapadula, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1046 - 1047
  • [35] Long-term safety of methotrexate in the treatment of rheumatoid arthritis
    Yazici, Y.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : S65 - S67
  • [36] PRORESID IN THE LONG-TERM TREATMENT OF RHEUMATOID-ARTHRITIS
    LYSHOLM, J
    WEITOFT, T
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (06) : 465 - 468
  • [37] TOLMETIN IN LONG-TERM TREATMENT OF RHEUMATOID-ARTHRITIS
    PAVELKA, K
    SUSTA, A
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1978, 24 (01): : 83 - 95
  • [38] LONG-TERM TREATMENT OF RHEUMATOID-ARTHRITIS WITH PERCLUSONE
    REJHOLEC, V
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 1975, 34 (5-6): : 141 - 148
  • [39] Long-term Safety of Rituximab in the Treatment of rheumatoid Arthritis
    Hoefler-Speckner, Simone
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2011, 18 (02): : 92 - 92
  • [40] LONG-TERM TREATMENT WITH INDOMETHACIN IN RHEUMATOID-ARTHRITIS
    BROELL, H
    EBERL, R
    TAUSCH, G
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1975, 4 : 93 - 93